SWKHMEDIUM SIGNALFINANCIAL10-K

SWKH underwent a business segment restructuring effective September 30, 2025, eliminating its two-segment reporting structure while generating substantially higher operating income despite asset base contraction.

The company discontinued its dual-segment operational model (Finance Receivables and Pharmaceutical Development) and appears to have exited advisory services, suggesting a strategic pivot or simplification. The meaningful improvement in operating performance alongside reduced credit losses indicates better asset quality, though the overall balance sheet contraction warrants monitoring.

Comparing 2026-03-20 vs 2025-03-20View on EDGAR →
FINANCIAL ANALYSIS

SWKH delivered substantially higher operating income while significantly reducing provision for credit losses, indicating improved asset quality and operational efficiency. However, the company experienced notable balance sheet contraction with total assets declining 18% to $272.4M and stockholders' equity falling to $235.1M, partially offset by reduced liabilities. Operating cash flow grew modestly to $27.3M while share buybacks were reduced by roughly half, suggesting a more conservative capital allocation approach during the business transition.

FINANCIAL STATEMENT CHANGES
Accounts Receivable
Balance Sheet
+99.4%
$528K$1.1M

Receivables surged 99.4% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Operating Income
P&L
+75%
$11.6M$20.3M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Share Buybacks
Cash Flow
-49%
$6.0M$3.1M

Buyback activity reduced 49% — capital being redeployed elsewhere or cash conservation underway.

Provision for Credit Losses
P&L
-45.2%
$3.5M$1.9M

Provisions reduced 45.2% — improving credit quality or reserve release boosting reported earnings.

R&D Expense
P&L
-29.6%
$2.2M$1.6M

R&D spending cut 29.6% — could signal cost discipline or concerning reduction in innovation investment.

Stockholders Equity
Balance Sheet
-18.6%
$288.7M$235.1M

Equity decreased 18.6% — buybacks or losses reducing book value, monitor solvency ratios.

Operating Cash Flow
Cash Flow
+18.4%
$23.0M$27.3M

Operating cash flow grew 18.4% — strong conversion of earnings to cash, healthy business fundamentals.

Total Assets
Balance Sheet
-18%
$332.2M$272.4M

Total assets contracted 18% — asset sales, write-downs, or balance sheet optimization underway.

Total Liabilities
Balance Sheet
-14.3%
$43.5M$37.3M

Liabilities reduced 14.3% — deleveraging improves balance sheet strength and financial flexibility.

Current Liabilities
Balance Sheet
-10.6%
$5.6M$5.0M

Current liabilities reduced — improved short-term financial position and working capital health.

LANGUAGE CHANGES
NEW — 2026-03-20
PRIOR — 2025-03-20
ADDED
Property and equipment, net consisted of the following (in thousands): December 31, 2025 December 31, 2024 Production equipment and other $ $ 4,079 Furniture and fixtures 139 198 Leasehold improvements 13 3,645 Capitalized software 16 192 Total 168 8,114 Less accumulated depreciation and amortization (120) (2,676) Property and equipment, net $ 48 $ 5,438 Depreciation and amortization expense on property and equipment was $0.9 million and $0.8 million for the year ended December 31, 2025 and 2024, respectively.
On March 16, 2026, the Registrant had outstanding approximat ely 12,095,979 shares of C ommon Stock, $0.001 par value per share.
We generally do not control our partner companies, and our partner companies may make decisions with which we don t agree or that don t serve our business or financial interests.
Public health epidemics, pandemics or outbreaks could adversely affect our and our partner companies businesses.
The announcement and pendency of the Mergers could adversely affect our businesses, financial results and operations.
+7 more — sign up free →
REMOVED
On March 13, 2025, the Registrant had outstanding approximat ely 12,252,816 shares of C ommon Stock, $0.001 par value per share.
We also own trademarks in several foreign countries and may pursue registration of other trademarks.
Our operations comprise two reportable segments: Finance Receivables and Pharmaceutical Development.
We allocate capital to each segment in order to generate income through the sales of life science products by third parties and related earned income sources.
In addition, through our wholly-owned subsidiary, SWK Advisors LLC, we are able to provide non-discretionary investment advisory services to institutional clients in separately managed accounts to similarly invest in life science finance.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →